Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$13.44M

FY 2025 · Annual

+11.0% YoY

Investing Cash Flow

-$292,000.00

FY 2025 · Annual

Financing Cash Flow

$6.98M

FY 2025 · Annual

+30.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.13M)(16.54M)(4.94M)8.55M17.38M
Depreciation & Amortization1.63M1.88M1.71M1.48M1.45M
Deferred Income Tax00000
Stock-Based Compensation6.2M5.74M4.75M3.66M6.07M
Change in Working Capital(4.73M)(6.01M)4.62M3.13M(8.3M)
Accounts Receivables(2.58M)(3.32M)2.26M(1.28M)(756K)
Inventory(1.92M)(1.08M)152K5.33M(11.64M)
Accounts Payables978K(744K)553K(1.07M)2.27M
Other Working Capital(1.21M)(875K)1.66M147K1.83M
Other Non-Cash Items(124K)(167K)977K(4.72M)(3.17M)
Operating Cash Flow(24.16M)(15.1M)7.12M12.11M13.44M
Capital Expenditures(409K)(334K)(148K)(163K)(292K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities005K20K0
Investing Cash Flow(409K)(334K)(143K)(143K)(292K)
Debt Repayment(31K)(16K)(15K)(11K)(12K)
Common Stock Issued26.74M7.75M05.43M7.25M
Common Stock Repurchased0000(251K)
Dividends Paid00000
Other Financing Activities9.39M(77K)(75K)(52K)0
Financing Cash Flow36.09M7.65M(90K)5.37M6.98M
Effect of Forex Changes00000
Net Change in Cash11.52M(7.78M)6.88M17.34M20.13M
Free Cash Flow(24.57M)(15.43M)6.97M11.95M13.15M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$17.4M
+ D&A$1.4M
+ Stock-Based Comp$6.1M
+ Deferred Tax$0
- Working Capital-$8.3M
- Other Non-Cash-$3.2M
= Operating Cash Flow$13.4M
- Capex-$292.0K
= Free Cash Flow$13.1M

Analysis

FY2025 free cash flow is $13.1M. FCF conversion is 75.6% of net income. Operating cash flow was $13.4M, with capex of -$292.0K. The largest bridge item is Working Capital at -$8.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 4, 2026

Does NAGE generate free cash flow?

Niagen Bioscience Inc (NAGE) generated $13.14M of free cash flow in fiscal 2025.

How much operating cash flow does NAGE produce?

Operating cash flow was $13.44M, before capital expenditures of $292,000.00.